Mitchell D. Creinin, MD

Find out what’s new and what this means for your practice.

Unveiling the intricate relationship between combined oral contraceptive use and breast cancer risk, navigating through research insights and clinical implications for informed patient counseling.

Clinicians need to stay up-to-date with medication and access issues.

Liletta is under study in a prospective phase 3 clinical trial aimed at extending the approved duration of this levonorgestrel 52-mg IUS.